Wedge Capital Management L L P NC Has $29.57 Million Holdings in United Therapeutics Corporation $UTHR

Wedge Capital Management L L P NC lessened its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 8.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 60,687 shares of the biotechnology company’s stock after selling 5,865 shares during the quarter. Wedge Capital Management L L P NC owned 0.14% of United Therapeutics worth $29,570,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Exchange Traded Concepts LLC grew its position in United Therapeutics by 31.5% in the fourth quarter. Exchange Traded Concepts LLC now owns 4,864 shares of the biotechnology company’s stock valued at $2,370,000 after purchasing an additional 1,164 shares in the last quarter. Pallas Capital Advisors LLC lifted its position in United Therapeutics by 147.6% during the 4th quarter. Pallas Capital Advisors LLC now owns 4,101 shares of the biotechnology company’s stock worth $1,998,000 after buying an additional 2,445 shares in the last quarter. Norden Group LLC acquired a new position in shares of United Therapeutics during the 4th quarter worth about $276,000. Willner & Heller LLC acquired a new position in shares of United Therapeutics during the 4th quarter worth about $201,000. Finally, E. Ohman J or Asset Management AB bought a new position in shares of United Therapeutics in the 4th quarter valued at about $741,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $522.83 on Friday. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $549.50. The stock has a market cap of $22.92 billion, a price-to-earnings ratio of 18.74, a PEG ratio of 1.92 and a beta of 0.84. The firm’s 50-day moving average is $495.95 and its 200-day moving average is $472.65.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. The business had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.United Therapeutics’s quarterly revenue was up 7.4% on a year-over-year basis. During the same quarter last year, the company posted $6.19 earnings per share. Sell-side analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on UTHR shares. Wells Fargo & Company lifted their target price on United Therapeutics from $466.00 to $486.00 and gave the company an “equal weight” rating in a research report on Monday, March 23rd. Royal Bank Of Canada increased their price target on United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. UBS Group boosted their price target on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Finally, HC Wainwright increased their price objective on United Therapeutics from $525.00 to $600.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $549.91.

Insider Activity at United Therapeutics

In related news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $9,956,712.48. The trade was a 34.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction on Monday, January 12th. The shares were sold at an average price of $479.51, for a total value of $10,788,975.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 356,320 shares of company stock valued at $176,808,253 over the last quarter. 10.30% of the stock is currently owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.